InnovHeart Achieves Milestone with First U.S. Saturn TMVR Implant for Mitral Valve Replacement

InnovHeart Makes History with First U.S. Saturn Transseptal TMVR Implant

InnovHeart, a forward-thinking medical device company, has recently announced a groundbreaking achievement in the field of cardiac care. The company successfully performed the inaugural implantation of its Saturn Transseptal Transcatheter Mitral Valve Replacement (TMVR) System on a patient in the United States. This procedure was conducted as part of the CASSINI-US Early Feasibility Study, marking a significant milestone in InnovHeart's clinical development program.

On August 25th, 2026, at the NewYork-Presbyterian/Columbia University Irving Medical Center in New York, Principal Investigator Dr. Torsten P. Vahl led the team that executed this pioneering procedure. The patient was an 86-year-old woman suffering from functional symptomatic severe mitral regurgitation, an ailment characterized by the backflow of blood due to improper closure of the heart's mitral valve.

Dr. Vahl and his team, including notable specialists such as Dr. Lauren S. Ranard, Dr. Isaac George, and Dr. Rebecca T. Hahn, utilized a percutaneous, transseptal approach to deliver the Saturn valve. The device was positioned within the patient’s native mitral valve, resulting in immediate success. Post-operation assessments showed favorable hemodynamic results, and the mitral regurgitation was effectively eliminated.

Dr. Vahl emphasized the importance of this first U.S. implantation for both their team and the broader development of transcatheter mitral valve replacement technology. He noted that the Saturn system includes innovative features aimed at overcoming challenges traditionally associated with TMVR, such as anatomical variability and the potential for left ventricular outflow tract (LVOT) obstruction. As they continue their clinical study, Dr. Vahl expressed optimism about the Saturn system's future.

The successful implantation represents not only a significant addition to InnovHeart's program but also the culmination of valuable clinical experience gained from the CASSINI-EU study conducted in Europe, where the Saturn device had already shown promising results.

Cumulatively, with the completion of the first U.S. procedure, InnovHeart has now treated a total of 15 patients globally as part of the CASSINI clinical program. This patient cohort includes individuals treated under the CASSINI-EU study, which has provided robust clinical follow-up data exceeding two years. Remarkably, there have been no procedural mortalities, no occurrences of LVOT obstruction, and 100% of implanted patients experienced a reduction in mitral regurgitation to mild or less.

David J. Wilson, CEO of InnovHeart, shared his enthusiasm over reaching this pivotal moment. He highlighted that the growing confidence in the Saturn system’s ability to address unmet clinical needs reinforces their commitment to establishing a foothold within the U.S. clinical landscape. This milestone paves the way for further advancements in providing effective treatment options for patients with mitral valve conditions.

Dr. Paolo Denti, who leads the CASSINI-EU study, echoed these sentiments, underscoring the consistency of positive clinical outcomes observed across both European and now U.S. patients. Sustained valve performance with no procedural mortality continues to be a cornerstone of the Saturn platform’s efficacy.

The CASSINI program aims to assess the technical feasibility, safety, and performance of the Saturn Transseptal TMVR System for patients suffering from moderate to severe symptomatic mitral regurgitation who qualify for transcatheter heart valve replacement. InnovHeart is committed to refining treatment methods for these patients, and with the U.S. milestone achieved, they look forward to what lies ahead in their research and development endeavors.

In summary, InnovHeart stands at the forefront of cardiac innovation with its Saturn TMVR system, now entered into clinical trials across the United States. This commitment to revolutionizing mitral valve replacements could significantly enhance patient care and outcomes in the coming years, making it an exciting time for both the company and the field of cardiac medicine.